Pliant Therapeutics (NASDAQ:PLRX) Announces Earnings Results, Beats Estimates By $0.17 EPS

Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.17, Zacks reports.

Pliant Therapeutics Trading Up 3.9 %

Pliant Therapeutics stock traded up $0.06 during mid-day trading on Thursday, hitting $1.58. The company's stock had a trading volume of 1,894,385 shares, compared to its average volume of 843,300. The firm has a market capitalization of $96.15 million, a PE ratio of -0.47 and a beta of 1.18. Pliant Therapeutics has a 1 year low of $1.26 and a 1 year high of $16.52. The company has a current ratio of 10.26, a quick ratio of 10.26 and a debt-to-equity ratio of 0.09. The stock's fifty day moving average is $8.35 and its two-hundred day moving average is $11.59.

Analysts Set New Price Targets

Several research firms recently commented on PLRX. Royal Bank of Canada cut their price target on Pliant Therapeutics from $4.00 to $3.00 and set a "sector perform" rating for the company in a report on Tuesday. Needham & Company LLC reaffirmed a "hold" rating and issued a $10.00 price target on shares of Pliant Therapeutics in a report on Tuesday. Canaccord Genuity Group reaffirmed a "hold" rating and issued a $4.00 price target (down previously from $43.00) on shares of Pliant Therapeutics in a report on Monday, February 10th. Leerink Partners cut Pliant Therapeutics from an "outperform" rating to a "market perform" rating and cut their price target for the company from $33.00 to $2.00 in a report on Monday. Finally, Stifel Nicolaus cut Pliant Therapeutics from a "buy" rating to a "hold" rating in a report on Monday. Twelve research analysts have rated the stock with a hold rating, According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $13.31.

Remove Ads

Insider Transactions at Pliant Therapeutics

In other news, General Counsel Mike Ouimette sold 10,230 shares of the firm's stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $10.99, for a total transaction of $112,427.70. Following the completion of the transaction, the general counsel now directly owns 70,544 shares in the company, valued at $775,278.56. This trade represents a 12.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Bernard Coulie sold 52,419 shares of the firm's stock in a transaction on Friday, January 17th. The stock was sold at an average price of $11.20, for a total value of $587,092.80. Following the transaction, the chief executive officer now owns 430,517 shares of the company's stock, valued at approximately $4,821,790.40. This represents a 10.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 91,855 shares of company stock worth $1,026,628 over the last ninety days. Company insiders own 6.40% of the company's stock.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.